A Study of DC6001 Tablet in Healthy Chinese Adult Subjects

Key facts

Sponsor

Heronova Pharmaceuticals

Intervention

DC6001(drug)

Enrollment

76 enrolled

Eligibility

18-55 years · All sexes

Timeline

2026 – 2026

Study locations (1)

• Beijing Tongren Hospital, Beijing, Beijing Municipality, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Stargardt disease

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07425574
  A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
  Astellas Pharma Global Development, Inc.
• RECRUITINGPHASE1, PHASE2NCT07439887
  Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease
  Ray Therapeutics, Inc.
• RECRUITINGPHASE1, PHASE2NCT07161544
  A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)
  AAVantgarde Bio Srl
• RECRUITINGPHASE1, PHASE2NCT06942572
  A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
  Splice Bio
• RECRUITINGNCT06445322
  Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)
  Ascidian Therapeutics, Inc
• RECRUITINGPHASE1, PHASE2NCT06467344
  Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
  Ascidian Therapeutics, Inc
• RECRUITINGNCT06591806
  An Observational Study in Children and Adults With Stargardt Disease
  AAVantgarde Bio Srl
• RECRUITINGNCT06435000
  An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
  Splice Bio

See all trials for Stargardt disease →